Ontology highlight
ABSTRACT:
PROVIDER: PRJNA379381 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR5349450_1.fastq.gz | Fastqsanger.gz | |||
| SRR5349450_2.fastq.gz | Fastqsanger.gz | |||
| SRR5349449_1.fastq.gz | Fastqsanger.gz | |||
| SRR5349449_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 4 of 4 |
Similar Datasets
Project description:Jurkat clone E6-1 is a human T-cell line derived from a paediatric case of acute leukaemia, and is frequently employed as a model T-cell for immunology research. In this study, we characterised genomic, transcriptomic, and functional features of Jurkat clone E6-1 cells stored in three different laboratories, and compared these to Jurkat E6-1 cells from the ATCC. Jurkat clone E6-1 populations were first karyotyped, which results showing marked cytogenomic heterogeneity between cell line. These results were confirmed through chromosomal microarray analysis. Whole exome sequencing was then conducted on each cell line, and revealed distinct mutational profiles between populations. Mutational differences between Jurkat clone E6-1 populations detected by cytogenomic approaches and whole exome sequencing led to divergent transcriptomic profiles identified by bulk RNA sequencing, which, in turn, impacted cellular phenotype and function shown by flow cytometry and multiplex cytokine bead array data. Overall, we found substantial genomic heterogeneity between and within Jurkat clone E6-1 cells, resulting in significant differences in gene expression and function. This research highlights the extreme genomic instability of Jurkat clone E6-1 cells, the importance of monitoring cell passage number and procuring fresh cell line stocks, and the value of multi-omic approaches to characterise cell lines to improve the accuracy, reproducibility, and translatability of research.
2025-04-08 | GSE263543 | GEO
Project description:Transcription profiling of human T cell leukaemia cell line Jurkat that were retrovirally transduced with constitutievely active forms of Notch to identify novel transcriptional targets of Notch signalling
2025-01-22 | E-MEXP-1744 | ExpressionAtlas
Project description:Altered metabolism is increasingly acknowledged as an important aspect of cancer, and thus serves as a potentially fertile area for the identification of therapeutic targets or leads. Our recent work using transcriptional data to predict metabolite levels in cancer cells led to preliminary evidence of the antiproliferative role of menaquinone (vitamin K2) in the Jurkat cell line model of acute lymphoblastic leukemia. However, nothing is known about the direct metabolic impacts of menaquinone in cancer, which could provide insights into its mechanism of action. Here, we used metabolomics to investigate the process by which menaquinone exerts antiproliferative activity on Jurkat cells. We first validated the dose-dependent, semi-selective, pro-apoptotic activity of menaquinone treatment on Jurkat cells relative to non-cancerous lymphoblasts. We then used mass spectrometry-based metabolomics to identify systems-scale changes in metabolic dynamics that are distinct from changes induced in noncancerous cells or by other chemotherapeutics. One of the most significantly affected metabolites was phosphoethanolamine, which exhibited a two-fold increase in menaquinone-treated Jurkat cells compared to vehicle-treated cells at 24 h, growing to a five-fold increase at 72 h. Phosphoethanolamine elevation was observed prior to the induction of apoptosis, and was not observed in menaquinonetreated lymphoblasts or chemotherapeutic-treated Jurkat cells. We also validated the link between menaquinone and phosphoethanolamine in an ovarian cancer cell line, suggesting potentially broad applicability of their relationship. This metabolomics-based work is the first detailed characterization of the metabolic impacts of menaquinone treatment and the first identified link between phosphoethanolamine and menaquinone-induced apoptosis.
2015-10-19 | MTBLS226 | MetaboLights
Project description:The cultured cell line Jurkat is frequently employed in studies of T cell function. Here we identified the microRNAs expressed in Jurkat cells in the presence and absence of CD3/CD28mAb treatment.
2010-12-31 | GSE23430 | GEO
Project description:The LEDGF transcript from the PSIP1 gene was knocked down in Jurkat cells using RNAi technology. The resulting Jurkat-derived cell line (Jurkat-siJK2) was compared to a control cell line (wild type Jurkat) using microarray analysis. Genes identified as being modulated by LEDGF were preferential targets of HIV integration. Keywords: effects of gene knockdown
2007-04-13 | GSE7508 | GEO
Project description:ChIP-seq analysis was performed in Jurkat cells (T-cell acute lymphoblastic leukemia cell line)
2018-01-12 | GSE97512 | GEO
Project description:ChIP-seq analysis was performed in Jurkat cells (T-cell acute lymphoblastic leukemia cell line)
2018-09-05 | GSE119439 | GEO
Project description:Biological and molecular characterization of CMA03/06, a newly established interleukin-6 independent variant of the CMA03 human myeloma cell line.
2025-01-24 | E-GEOD-39685 | ExpressionAtlas
Project description:Colorectal cancer cell line proteomes
2021-05-25 | E-PROT-18 | ExpressionAtlas
Project description:screenning the differentially expressed genes of Jurkat-FF3, Jurkat-miR146a, Jurkat-miR146a-sponge cell lines. To investigate the role of miR-146a on Jurkat T cells, we screened the differentially expressed genes of Jurkat-FF3 (as control), Jurkat-miR146a (as miR-146a overexpression cell line), Jurkat-miR146a-sponge (as miR-146a knock down cell line).
2010-04-03 | E-GEOD-21132 | biostudies-arrayexpress